4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 18.49K shares.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 198.90K shares.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 130.01K shares, a 2000.40% increase year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 31.09K shares, a 56.69% decline year-over-year.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 163.10K shares, a 56.41% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 374.15K shares, a 34.90% decline from fiscal 2023.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 574.74K shares, a 97.08% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 291.63K shares, a 48.24% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 18.49K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 378.50K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 198.90K shares 10-Q · filed 2026-05-07 | |
| 2025-12-31 | 130.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | 163.10K shares 10-K · filed 2026-03-18 |
| 2025-09-30 | 31.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-12-31 | 6.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 374.15K shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 71.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 623.13K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 70.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 676.50K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 225.86K shares 10-Q · filed 2024-05-09 | 678.39K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 255.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 574.74K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 125.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 504.90K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 72.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 395.25K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 122.21K shares 10-Q · filed 2023-05-11 | 374.30K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 185.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 291.63K shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 15.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 226.09K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 51.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 484.31K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 39.54K shares 10-Q · filed 2022-05-12 | 590.53K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 119.79K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 563.39K shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 273.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2021-06-30 | 157.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 12.40K shares 10-Q · filed 2021-05-13 | |
| 2020-12-31 | 267.04K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |